X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PANACEA BIOTECH - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PANACEA BIOTECH AUROBINDO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 20.1 -6.7 - View Chart
P/BV x 3.8 2.0 187.8% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 AUROBINDO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
PANACEA BIOTECH
Mar-14
AUROBINDO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs809149 544.0%   
Low Rs50482 612.4%   
Sales per share (Unadj.) Rs281.184.1 334.0%  
Earnings per share (Unadj.) Rs41.4-18.3 -225.9%  
Cash flow per share (Unadj.) Rs50.9-6.7 -759.5%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.483.7 238.2%  
Shares outstanding (eoy) m585.8861.25 956.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.4 170.2%   
Avg P/E ratio x15.9-6.3 -251.6%  
P/CF ratio (eoy) x12.9-17.2 -74.8%  
Price / Book Value ratio x3.31.4 238.7%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6307,074 5,436.9%   
No. of employees `00017.32.8 630.3%   
Total wages/salary Rs m21,3081,449 1,470.4%   
Avg. sales/employee Rs Th9,500.71,874.1 507.0%   
Avg. wages/employee Rs Th1,229.4527.0 233.3%   
Avg. net profit/employee Rs Th1,397.9-407.7 -342.8%   
INCOME DATA
Net Sales Rs m164,6665,154 3,195.1%  
Other income Rs m1,020100 1,021.8%   
Total revenues Rs m165,6865,254 3,153.8%   
Gross profit Rs m37,718-766 -4,922.0%  
Depreciation Rs m5,580711 784.8%   
Interest Rs m7771,503 51.7%   
Profit before tax Rs m32,380-2,881 -1,124.1%   
Minority Interest Rs m3111 290.7%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m8,18317 48,706.5%   
Profit after tax Rs m24,229-1,121 -2,160.8%  
Gross profit margin %22.9-14.9 -154.0%  
Effective tax rate %25.3-0.6 -4,332.8%   
Net profit margin %14.7-21.8 -67.6%  
BALANCE SHEET DATA
Current assets Rs m121,8783,810 3,198.7%   
Current liabilities Rs m86,8068,365 1,037.7%   
Net working cap to sales %21.3-88.4 -24.1%  
Current ratio x1.40.5 308.3%  
Inventory Days Days130156 83.4%  
Debtors Days Days6867 101.7%  
Net fixed assets Rs m81,03714,480 559.6%   
Share capital Rs m58661 955.8%   
"Free" reserves Rs m116,218903 12,868.8%   
Net worth Rs m116,8045,127 2,278.1%   
Long term debt Rs m4,5125,832 77.4%   
Total assets Rs m211,05219,433 1,086.0%  
Interest coverage x42.7-0.9 -4,655.0%   
Debt to equity ratio x01.1 3.4%  
Sales to assets ratio x0.80.3 294.2%   
Return on assets %11.82.0 603.2%  
Return on equity %20.7-21.9 -94.8%  
Return on capital %27.43.6 752.3%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m80,7271,539 5,244.8%   
Fx outflow Rs m34,700942 3,683.7%   
Net fx Rs m46,027597 7,707.1%   
CASH FLOW
From Operations Rs m19,548599 3,262.4%  
From Investments Rs m-19,570-438 4,468.9%  
From Financial Activity Rs m8,642-303 -2,855.8%  
Net Cashflow Rs m8,922-141 -6,314.3%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.6 1,325.0%  
FIIs % 27.7 1.3 2,130.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.6 43.2%  
Shareholders   69,601 10,259 678.4%  
Pledged promoter(s) holding % 8.6 35.1 24.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FDC LTD.  UNICHEM LAB  WYETH LTD  ELDER PHARMA  ALEMBIC LTD  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 7, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - BIOCON LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS